Compare Manchester United PLC (MANU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Manchester United PLC trades at $22.23 (market cap $3.74B), while Vertex Pharmaceuticals Incorporated trades at $528.02 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 35.5× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MANU | VRTX | |
|---|---|---|
Market Cap | $3.74B | $132.79B |
Sector | Media | Health |
52-Week High | $23.53 | $529.65 |
52-Week Low | $15.10 | $376.62 |
Enterprise Value | $4.68B | $126.92B |
Dividend Yield | 1.26% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
